Medicine and Dentistry
Chronic Kidney Disease
100%
Kidney Graft
74%
Kidney Function
71%
Cardiovascular System
68%
Glomerular Filtration Rate
64%
Maturity Onset Diabetes of the Young
64%
Nephropathy
60%
Urinary System
56%
Diabetes
50%
Heart Failure
50%
Disease
47%
Albuminuria
46%
Kidney Transplantation
44%
Cardiovascular Disease
42%
Proteinuria
38%
Creatinine
37%
Biological Marker
34%
Blood Pressure
34%
Diabetes Mellitus
30%
Hazard Ratio
30%
Polycystic Kidney Disease
30%
Placebo
29%
Patient with Type 2 Diabetes
29%
Diabetic Nephropathy
29%
Cardiovascular Risk
26%
Meta-Analysis
26%
Transplantation
25%
Cohort Analysis
24%
Kidney Injury
23%
Canagliflozin
23%
Population
22%
Endothelial Cell
21%
Graft Failure
21%
End Stage Renal Disease
21%
Clinical Trial
20%
Renal Failure
20%
Quality of Life
18%
Randomized Controlled Trial
18%
Autofluorescence
17%
Renin Angiotensin Aldosterone System
17%
Vasculitis
17%
Advanced Glycation End-Product
17%
Body Mass Index
16%
Atherosclerosis
16%
Post-Hoc Analysis
16%
Sodium Intake
15%
All Cause Mortality
15%
In Vitro
15%
Intima-Media Thickness
15%
Systematic Review
15%
Prevalence
15%
COVID-19
15%
Sodium Glucose Cotransporter 2 Inhibitor
14%
Disease Exacerbation
14%
Oxidative Stress
14%
ACE Inhibitor
13%
ANCA Associated Vasculitis
13%
Microalbuminuria
13%
Neutrophil
13%
Hemodialysis
12%
Injury
12%
Dipeptidyl Carboxypeptidase
12%
Autoantibodies
12%
Glomerulonephritis
12%
Myeloperoxidase
12%
Dapagliflozin
12%
Angiotensin II
12%
Proportional Hazards Model
11%
Sepsis
11%
Infection
11%
Insulin Dependent Diabetes Mellitus
11%
Atrial Fibrillation
11%
Sodium Restriction
11%
Drug Therapy
10%
Fibrosis
10%
Systolic Blood Pressure
10%
Prospective Cohort Study
10%
Hemodynamic
10%
Acute Kidney Injury
10%
C Reactive Protein
10%
Renal Replacement Therapy
10%
Terminal Illness
10%
Observational Study
10%
Macrophage
10%
Adverse Event
9%
Myocardial Infarction
9%
Cardiovascular Mortality
9%
Supplementation
9%
Endothelial Dysfunction
9%
Diagnosis
9%
High Density Lipoprotein Cholesterol
9%
Renal Protection
9%
Hemoglobin A1c
9%
Enzyme Inhibition
9%
Granulomatosis with Polyangiitis
8%
Gene Expression
8%
Pathophysiology
8%
Fibroblast Growth Factor 23
8%
Kidney Blood Flow
8%
Apoplexy
8%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
92%
Chronic Kidney Failure
89%
Heart Failure
69%
Creatinine
53%
Kidney Disease
53%
Albuminuria
51%
Disease
49%
Placebo
47%
Cardiovascular Disease
42%
Biological Marker
35%
Diabetic Nephropathy
31%
All Cause Mortality
30%
Dapagliflozin
28%
Diabetes Mellitus
28%
Cardiovascular Risk
27%
Inflammation
26%
Renin
25%
Clinical Trial
24%
Canagliflozin
23%
Angiotensin
22%
End Stage Renal Disease
21%
Dipeptidyl Carboxypeptidase Inhibitor
20%
Proteinuria
20%
Sodium Glucose Cotransporter 2 Inhibitor
19%
Prevalence
19%
Kidney Failure
18%
Cohort Study
18%
Kidney Injury
18%
Kidney Polycystic Disease
17%
Cardiovascular Mortality
17%
Graft Failure
17%
Randomized Controlled Trial
16%
Mouse
15%
Brain Natriuretic Peptide
14%
Advanced Glycation End Product
14%
C Reactive Protein
14%
Aldosterone
14%
Heart Infarction
14%
Angiotensin II
14%
Microalbuminuria
14%
Adverse Event
13%
Atrial Fibrillation
13%
Receptor
13%
Angiotensin Receptor Antagonist
13%
Terminal Illness
12%
Disease Exacerbation
12%
Dipeptidyl Carboxypeptidase
12%
Fibrosis
12%
Atherosclerosis
11%
Prospective Cohort Study
11%
Hemoglobin A1c
11%
Insulin Dependent Diabetes Mellitus
10%
Losartan
10%
Hemodialysis
10%
Antihypertensive Agent
10%
Acute Heart Failure
10%
Anemia
9%
Injury
9%
Infection
9%
Sepsis
9%
Observational Study
9%
Pharmacokinetics
8%
ANCA Associated Vasculitis
8%
Tolvaptan
8%
Prospective Study
8%
High Density Lipoprotein Cholesterol
8%
Thiol
8%
Randomized Clinical Trial
8%
Hydrogen Sulfide
8%
Acute Kidney Failure
8%
Adverse Outcome
8%
Pathophysiology
8%
Reperfusion Injury
8%
Fibroblast Growth Factor 23
8%
Atrasentan
7%
Isotopes of Potassium
7%
Myeloperoxidase
7%
Diuretic Agent
7%
Malignant Neoplasm
7%
Replacement Therapy
7%
Autoantibodies
7%
Metabolic Syndrome X
6%
Low Density Lipoprotein Cholesterol
6%
Wegener Granulomatosis
6%
Erythropoietin
6%
Copeptin
6%
Insulin Resistance
6%
Enzyme Inhibition
6%
Hydrocortisone
6%
Ischemia
6%
Rat Model
6%
Heart Failure with Reduced Ejection Fraction
6%
Neoplasm
6%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
6%
Congestive Heart Failure
6%
Normal Human
6%
Venous Thromboembolism
6%
Symptom
5%
Reactive Oxygen Metabolite
5%
Kidney Injury Molecule 1
5%
Keyphrases
Chronic Kidney Disease
53%
Type 2 Diabetes Mellitus (T2DM)
44%
Albuminuria
37%
Estimated Glomerular Filtration Rate
34%
Type 2 Diabetic Patients
34%
Confidence Interval
28%
Kidney Transplant Recipients
27%
Hazard Ratio
23%
All-cause Mortality
22%
Kidney
20%
Heart Failure
20%
Dapagliflozin
20%
Albumin-to-creatinine Ratio
19%
Diabetes
19%
Canagliflozin
19%
Diabetic Kidney Disease
18%
Cardiovascular Mortality
18%
Placebo
17%
Renal Transplant Recipients
17%
Cardiovascular Risk
17%
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
16%
Proteinuria
16%
Blood Pressure
16%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
15%
Cardiovascular Outcomes
15%
Renal Function
14%
Kidney Function
14%
Meta-analysis
14%
Cardiovascular Disease
14%
Kidney Transplantation
14%
Cardiovascular Events
12%
Type 1 Diabetes Mellitus (T1DM)
11%
Prospective Cohort Study
11%
Glomerular Filtration Rate
11%
Risk Factors
11%
End-organ Disease
11%
Kidney Outcomes
11%
Hypertension
10%
High Risk
10%
Diabetic Nephropathy
10%
Body Mass Index
10%
Patients with Heart Failure
9%
Netherlands
9%
Kidney Disease Progression
9%
Transplantation
9%
Urinary Albumin Excretion
9%
Kidney Failure
9%
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
9%
Skin Autofluorescence
9%
COVID-19
9%
Clinical Trials
8%
Atrial Fibrillation
8%
Nephropathy
8%
Free Thiols
8%
Angiotensin-converting Enzyme Inhibitor (ACEi)
8%
Renal Disease
8%
Renal Outcome
8%
Dutch
8%
Randomized Controlled Trial
8%
Advanced Glycation End Products
7%
Patients with Diabetes
7%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
7%
Kidney Disease
7%
Oxidative Stress
7%
Obesity
7%
Clinical Outcomes
7%
Randomized Clinical Trial
7%
Egfr
7%
Graft Failure
7%
Fibroblast Growth Factor 23 (FGF23)
7%
Microalbuminuria
7%
High-density Lipoprotein Cholesterol (HDL-C)
7%
Health-related Quality of Life
7%
Healthy Controls
6%
Angiotensin Receptor Blockers
6%
Heart Failure with Preserved Ejection Fraction (HFpEF)
6%
Living Kidney Donor
6%
Adverse Outcomes
6%
Inflammation
6%
Hemoglobin A1c (HbA1c)
6%
Chronic Heart Failure
6%
Renal Function Decline
6%
Antineutrophil Cytoplasmic Antibody
6%
Systolic Blood Pressure
6%
ANCA-associated Vasculitis
5%
Mortality Risk
5%
Acute Heart Failure
5%
Cardiovascular Assessment
5%
Risk Markers
5%
Angiotensin II (Ang II)
5%
Pretransplant
5%
Chronic Kidney Disease Patients
5%
Renal Events
5%
Assessment Study
5%
Systematic Meta-analysis
5%
Credence
5%
Biobank
5%
Creatinine
5%
Renal Hemodynamics
5%
End-stage Renal Disease
5%